ArticleMolecular and clinical oncology2025
Effect of anamorelin treatment duration on survival of patients with cancer cachexia: A retrospective study.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation.Annals of nutrition & metabolism · 2026Article
- Recent developments in GPCR signalling in appetite regulation.Bioscience reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world data on the effectiveness of anamorelin in managing cancer cachexia remains limited, particularly as its availability is currently restricted to Japan. In the present study, anamorelin use in cancer cachexia management was retrospectively evaluated, focusing on patient characteristics and survival after both short- and long-term use. Patients prescribed anamorelin between August 2021 and January 2024 at the Saitama Canc2er Center (Ina, Japan) were included. Medical records were reviewed to collect baseline characteristics at anamorelin treatment initiation. The patients were divided into two groups: short- and long-treatment groups (STT and LTT, respectively). Overall, 60 and 69 patients were included in the STT and LTT groups, respectively. Significant intergroup differences were found in age (P=0.021), gastric cancer incidence rate (P=0.013), albumin level of <3.5 g/dl (P=0.044) and Eastern Cooperative Oncology Group performance status score (P=0.008). The longest median time from diagnosis to anamorelin treatment initiation was observed for colorectal cancer, while the longest median anamorelin treatment duration was observed for lung cancer. The median survival durations during anamorelin treatment were 49 and 142 days in the STT and LTT groups, respectively (P<0.001). The corresponding median survival durations after anamorelin treatment termination in the STT and LTT groups were 38 and 34 days (P=0.554), respectively. Anamorelin treatment duration influenced patient survival, with post-discontinuation survival being ~1 month, regardless of treatment length.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.